Expression levels of IL-37 and HBeAg seroconversion in chronic HBV patients
10.3969/j.issn.1000-484X.2015.11.023
- VernacularTitle:慢性乙型肝炎患者中IL-37的水平与HBeAg血清转换的关系研究
- Author:
Jingjing LIU
;
Qingyan LI
;
Shan GUAN
;
Chunhua LIU
;
Yukai HE
;
Changming TAO
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Interleukin-37;
Telbivudine;
HBeAg seroconversion
- From:
Chinese Journal of Immunology
2015;(11):1545-1548,1552
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Detecting serum IL-37 concentrations and HBeAg seroconversion in chronic hepatitis B virus(HBV) patients during the treatment of telbivudine( LDT).Methods:Fifty patients with chronic hepatitis B were included in the study;and 20 healthy people were selected as the control group.The expression levels of interleukin ( IL)-37, IL-6 and CRP were measured by enzyme-linked immunosorbent assay.As the same time,the relationship between serum IL-37 concentrations and HBeAg seroconversion was dynamically observed at 0 w,12 w,24 w,36 w,48 w after treatment.Results:The serum levels of IL-37 in chronic HBV patients were higher than the control group at baseline(q=22.716,P<0.01).The serum levels of IL-37 were decreased in HBeAg seroconverted CHB patients(t=-19.480,P<0.001).The levels of IL-37 were positively correlated with ALT,IL-6 and CRP(r were 0.697,0.725, 0.895,respectively;all P<0.001).The levels of IL-37 and HBV DNA was no correlation(r=0.136,P>0.05).Conclusion:IL-37 may be involved in the process of HBV infection in CHB patients,and can reflect the degree of liver’ s inflammatory damage.IL-37 may play a significant role in the immune response of CHB patients with HBeAg seroconversion.In future,IL-37 may be an effective therapeutic measure to HBV infection.
